CY1115233T1 - Υγρα σταθεροποιημενα σκευασματα ιντερφερονης-βητα σε επικαλυμμενους περιεκτες φαρμακευτικης χρησης - Google Patents
Υγρα σταθεροποιημενα σκευασματα ιντερφερονης-βητα σε επικαλυμμενους περιεκτες φαρμακευτικης χρησηςInfo
- Publication number
- CY1115233T1 CY1115233T1 CY20141100386T CY141100386T CY1115233T1 CY 1115233 T1 CY1115233 T1 CY 1115233T1 CY 20141100386 T CY20141100386 T CY 20141100386T CY 141100386 T CY141100386 T CY 141100386T CY 1115233 T1 CY1115233 T1 CY 1115233T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical uses
- interferon
- liquid stabilized
- stabilized interferon
- covered
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title abstract 3
- 108090000467 Interferon-beta Proteins 0.000 title abstract 3
- 229960001388 interferon-beta Drugs 0.000 title abstract 3
- 239000007788 liquid Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229930195722 L-methionine Natural products 0.000 abstract 1
- 239000004809 Teflon Substances 0.000 abstract 1
- 229920006362 Teflon® Polymers 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229960004452 methionine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001993 poloxamer 188 Polymers 0.000 abstract 1
- 229940044519 poloxamer 188 Drugs 0.000 abstract 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/002—Closures to be pierced by an extracting-device for the contents and fixed on the container by separate retaining means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/005—Closures provided with linings or internal coatings so as to avoid contact of the closure with the contents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mechanical Engineering (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03010671 | 2003-05-13 | ||
| EP04760770.0A EP1633388B1 (en) | 2003-05-13 | 2004-05-12 | Liquid stabilized interferon-beta formulations in coated pharmaceutical containers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115233T1 true CY1115233T1 (el) | 2017-01-04 |
Family
ID=33442722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100386T CY1115233T1 (el) | 2003-05-13 | 2014-05-30 | Υγρα σταθεροποιημενα σκευασματα ιντερφερονης-βητα σε επικαλυμμενους περιεκτες φαρμακευτικης χρησης |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7540382B2 (https=) |
| EP (2) | EP2324845A1 (https=) |
| JP (2) | JP2007502684A (https=) |
| KR (1) | KR101084412B1 (https=) |
| CN (1) | CN1809376B (https=) |
| AR (1) | AR044302A1 (https=) |
| AU (1) | AU2004237982C1 (https=) |
| BR (1) | BRPI0410679A (https=) |
| CA (1) | CA2523477A1 (https=) |
| CY (1) | CY1115233T1 (https=) |
| DK (1) | DK1633388T3 (https=) |
| EA (1) | EA008308B1 (https=) |
| ES (1) | ES2471942T3 (https=) |
| HR (1) | HRP20140267T1 (https=) |
| IL (1) | IL171912A (https=) |
| MX (1) | MXPA05012191A (https=) |
| NO (1) | NO20055774D0 (https=) |
| PL (1) | PL1633388T3 (https=) |
| PT (1) | PT1633388E (https=) |
| SI (1) | SI1633388T1 (https=) |
| UA (1) | UA91493C2 (https=) |
| WO (1) | WO2004100979A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007538048A (ja) * | 2004-05-17 | 2007-12-27 | アレス トレーディング ソシエテ アノニム | ヒドロゲル・インターフェロン製剤 |
| UA92146C2 (ru) * | 2004-06-01 | 2010-10-11 | Эйрэс Трейдинг С.А. | Стабилизированная жидкая композиция, которая содержит интерферон |
| PT1845925T (pt) * | 2005-01-12 | 2016-11-22 | Biogen Ma Inc | Método para distribuir interferão-beta |
| WO2007016562A2 (en) * | 2005-07-29 | 2007-02-08 | Amgen Inc. | Formulations that inhibit protein aggregation |
| WO2007127668A2 (en) * | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| KR100785070B1 (ko) | 2006-07-11 | 2007-12-12 | 삼성전자주식회사 | 휴대 단말기에서 디지털 저작권 관리 콘텐츠 재생 방법 및장치 |
| EP2170268A2 (en) | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| BRPI0821029A2 (pt) * | 2007-12-20 | 2015-06-16 | Merck Serono Sa | Fomulações de peg-interferon-beta |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| JP6214161B2 (ja) | 2009-12-21 | 2017-10-18 | ジェネンテック， インコーポレイテッド | 抗体製剤 |
| US8802603B2 (en) | 2010-06-17 | 2014-08-12 | Becton, Dickinson And Company | Medical components having coated surfaces exhibiting low friction and low reactivity |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| FR2966044B1 (fr) * | 2010-10-18 | 2012-11-02 | Sanofi Pasteur | Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| TW202244057A (zh) | 2012-12-03 | 2022-11-16 | 美商諾維生物製藥有限公司 | 新穎縮肽及其用途 |
| CA2926301A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2014159554A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
| EP4137139A1 (en) | 2013-07-10 | 2023-02-22 | Matrix Biology Institute | Compositions of hyaluronan with high elasticity and uses thereof |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| EP3041803B1 (en) * | 2014-03-13 | 2019-11-27 | Stevanato Group International A. S. | Method of handling a liquid drug formulation |
| US20170226552A1 (en) | 2014-07-03 | 2017-08-10 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
| WO2016007764A1 (en) | 2014-07-09 | 2016-01-14 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars |
| WO2016144773A1 (en) | 2015-03-06 | 2016-09-15 | Abbvie Inc. | Arabinosylated glycoproteins |
| WO2016163764A2 (ko) * | 2015-04-07 | 2016-10-13 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
| PL3352766T3 (pl) | 2015-09-24 | 2021-08-02 | Matrix Biology Institute | Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia |
| WO2017147003A1 (en) | 2016-02-26 | 2017-08-31 | Novobiotic Pharmaceuticals, Llc | Novel macrocyclic antibiotics and uses thereof |
| FI126979B (en) | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and its use |
| EP3606941B1 (en) | 2017-04-04 | 2024-05-01 | Novobiotic Pharmaceuticals, LLC | Novel depsipeptides and uses thereof |
| US12161777B2 (en) | 2020-07-02 | 2024-12-10 | Davol Inc. | Flowable hemostatic suspension |
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
| EP4267210A1 (en) | 2020-12-28 | 2023-11-01 | Davol Inc. | Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2622598A (en) | 1951-03-08 | 1952-12-23 | Premo Pharmaceutical Lab Inc | Drain-clear container for aqueous liquid pharmaceutical preparations |
| US5183746A (en) | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| EP0639114B1 (en) * | 1992-05-06 | 2000-08-09 | Mallinckrodt Inc. | Container and closure system for maintaining stability of sodium hypochlorite solutions |
| US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| TW249202B (https=) * | 1993-08-13 | 1995-06-11 | Ciba Gerigy Corp | |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| DK0862452T3 (da) * | 1995-11-07 | 2004-04-05 | Genentech Inc | Stabiliserende formulering af NGF |
| US6142977A (en) | 1996-10-18 | 2000-11-07 | Schering Ag | Prefilled, sterilized syringe with a new and improved plug |
| JP4878664B2 (ja) * | 1996-12-24 | 2012-02-15 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定な液体インターフェロン処方物 |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CN2326243Y (zh) | 1997-09-29 | 1999-06-30 | 程继勇 | 覆膜药用瓶塞 |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| CN2441750Y (zh) * | 2000-06-23 | 2001-08-08 | 程继勇 | 表面覆膜药用橡胶瓶塞 |
| JP2002209975A (ja) * | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| CN1133565C (zh) * | 2001-10-18 | 2004-01-07 | 郑秀娣 | 药品瓶塞隔离膜 |
-
2004
- 2004-05-11 AR ARP040101607 patent/AR044302A1/es not_active Application Discontinuation
- 2004-05-12 CN CN2004800169917A patent/CN1809376B/zh not_active Expired - Lifetime
- 2004-05-12 UA UAA200510442A patent/UA91493C2/uk unknown
- 2004-05-12 DK DK04760770T patent/DK1633388T3/da active
- 2004-05-12 MX MXPA05012191A patent/MXPA05012191A/es active IP Right Grant
- 2004-05-12 PL PL04760770T patent/PL1633388T3/pl unknown
- 2004-05-12 EP EP20110152658 patent/EP2324845A1/en not_active Withdrawn
- 2004-05-12 CA CA 2523477 patent/CA2523477A1/en not_active Withdrawn
- 2004-05-12 SI SI200432149T patent/SI1633388T1/sl unknown
- 2004-05-12 WO PCT/EP2004/050779 patent/WO2004100979A2/en not_active Ceased
- 2004-05-12 EA EA200501692A patent/EA008308B1/ru not_active IP Right Cessation
- 2004-05-12 ES ES04760770.0T patent/ES2471942T3/es not_active Expired - Lifetime
- 2004-05-12 AU AU2004237982A patent/AU2004237982C1/en not_active Expired
- 2004-05-12 JP JP2006530185A patent/JP2007502684A/ja not_active Withdrawn
- 2004-05-12 KR KR20057021160A patent/KR101084412B1/ko not_active Expired - Fee Related
- 2004-05-12 US US10/556,467 patent/US7540382B2/en not_active Ceased
- 2004-05-12 US US13/151,459 patent/USRE43331E1/en not_active Expired - Lifetime
- 2004-05-12 HR HRP20140267TT patent/HRP20140267T1/hr unknown
- 2004-05-12 BR BRPI0410679 patent/BRPI0410679A/pt not_active IP Right Cessation
- 2004-05-12 PT PT04760770T patent/PT1633388E/pt unknown
- 2004-05-12 EP EP04760770.0A patent/EP1633388B1/en not_active Expired - Lifetime
-
2005
- 2005-11-13 IL IL17191205A patent/IL171912A/en active IP Right Grant
- 2005-12-06 NO NO20055774A patent/NO20055774D0/no not_active Application Discontinuation
-
2012
- 2012-01-13 JP JP2012005485A patent/JP2012096063A/ja active Pending
-
2014
- 2014-05-30 CY CY20141100386T patent/CY1115233T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115233T1 (el) | Υγρα σταθεροποιημενα σκευασματα ιντερφερονης-βητα σε επικαλυμμενους περιεκτες φαρμακευτικης χρησης | |
| CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
| MY162623A (en) | Immunoglobulin formulation and method of preparation thereof | |
| EA200401019A1 (ru) | Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества | |
| CY1108361T1 (el) | ΣΤΑΘΕΡΟ ΣΚΕΥΑΣΜΑ ΠΟΥ ΠΕΡΙΕΧΕΙ TNFR-Fc ΚΑΙ ΑΡΓΙΝΙΝΗ | |
| DK1197221T3 (da) | Langtidsstabiliserede G-CSF-præparater | |
| BR0014486A (pt) | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado | |
| CY1106420T1 (el) | Νανοσωματιδιακα σκευασματα ινσουλινης | |
| PE20050438A1 (es) | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos | |
| BRPI0311877B8 (pt) | formulação farmacêutica ácida de insulina com estabilidade aperfeiçoada | |
| JP2007502684A5 (https=) | ||
| AR020048A1 (es) | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. | |
| ID26033A (id) | Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan | |
| PE20000560A1 (es) | Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| DE3684220D1 (de) | Zusammensetzung mit verzoegerter abgabe. | |
| EA200501699A1 (ru) | Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин | |
| ATE526032T1 (de) | Stabilisierte flüssige interferon-formulierungen | |
| SE8702734D0 (sv) | Monoclonal antibodies to pseudomonas aeruginosa flagella | |
| CY1105540T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει ξανθανικο κομμι | |
| ES2179667T3 (es) | Nuevas formulaciones inyectables que contienen ramoplanina. | |
| DE60225117D1 (de) | Behältnis mit niedrigem sauerstoffgehalt, das ff-mas enthält | |
| BR0202759A (pt) | Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa | |
| SV1999000067A (es) | Proteina humana c polipeptida ref. x-12279 | |
| CY1113904T1 (el) | Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg |